CSPC Pharmaceutical Group 미래 성장
Future 기준 확인 1/6
CSPC Pharmaceutical Group (는) 각각 연간 2.7% 및 3.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.3% 로 예상됩니다.
주요 정보
2.7%
수익 성장률
2.0%
EPS 성장률
Pharmaceuticals 수익 성장 | 10.8% |
매출 성장률 | 3.8% |
향후 자기자본 수익률 | 10.3% |
애널리스트 커버리지 | Good |
마지막 업데이트 | 25 Nov 2024 |
최근 미래 성장 업데이트
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29Recent updates
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 33,916 | 5,953 | 4,764 | N/A | 25 |
12/31/2025 | 32,275 | 5,626 | 4,428 | N/A | 28 |
12/31/2024 | 30,605 | 5,209 | 4,270 | N/A | 24 |
9/30/2024 | 30,271 | 5,157 | N/A | N/A | N/A |
6/30/2024 | 31,654 | 5,927 | 2,672 | 4,284 | N/A |
3/31/2024 | 32,380 | 6,057 | N/A | N/A | N/A |
12/31/2023 | 31,450 | 5,873 | 2,290 | 4,179 | N/A |
9/30/2023 | 31,306 | 6,118 | N/A | N/A | N/A |
6/30/2023 | 31,407 | 6,092 | 1,934 | 4,690 | N/A |
3/31/2023 | 31,116 | 6,116 | N/A | N/A | N/A |
12/31/2022 | 30,937 | 6,091 | 4,922 | 7,627 | N/A |
9/30/2022 | 30,721 | 5,738 | N/A | N/A | N/A |
6/30/2022 | 29,655 | 5,509 | 4,094 | 6,151 | N/A |
3/31/2022 | 29,007 | 5,538 | N/A | N/A | N/A |
12/31/2021 | 27,867 | 5,605 | 2,887 | 4,637 | N/A |
9/30/2021 | 26,369 | 5,977 | N/A | N/A | N/A |
6/30/2021 | 26,175 | 5,908 | 5,865 | 7,053 | N/A |
3/31/2021 | 25,551 | 5,472 | N/A | N/A | N/A |
12/31/2020 | 24,942 | 5,160 | 5,362 | 6,740 | N/A |
9/30/2020 | 24,558 | 4,421 | N/A | N/A | N/A |
6/30/2020 | 23,515 | 4,150 | 3,129 | 4,614 | N/A |
3/31/2020 | 22,735 | 3,922 | N/A | N/A | N/A |
12/31/2019 | 22,103 | 3,714 | 1,835 | 3,784 | N/A |
9/30/2019 | 21,335 | 3,625 | N/A | N/A | N/A |
6/30/2019 | 20,135 | 3,454 | 1,370 | 3,743 | N/A |
3/31/2019 | 18,835 | 3,294 | N/A | N/A | N/A |
12/31/2018 | 17,717 | 3,081 | 1,922 | 3,795 | N/A |
9/30/2018 | 16,877 | 2,905 | N/A | N/A | N/A |
6/30/2018 | 15,729 | 2,734 | N/A | 3,352 | N/A |
3/31/2018 | 13,959 | 2,443 | N/A | N/A | N/A |
12/31/2017 | 12,877 | 2,307 | N/A | 2,738 | N/A |
9/30/2017 | 12,203 | 2,195 | N/A | N/A | N/A |
6/30/2017 | 11,659 | 2,068 | N/A | 2,811 | N/A |
3/31/2017 | 11,383 | 1,979 | N/A | N/A | N/A |
12/31/2016 | 11,075 | 1,881 | N/A | 2,611 | N/A |
9/30/2016 | 10,439 | 1,711 | N/A | N/A | N/A |
6/30/2016 | 10,118 | 1,607 | N/A | 2,147 | N/A |
3/31/2016 | 9,656 | 1,473 | N/A | N/A | N/A |
12/31/2015 | 9,545 | 1,395 | N/A | 1,884 | N/A |
9/30/2015 | 9,284 | 1,305 | N/A | N/A | N/A |
6/30/2015 | 9,072 | 1,192 | N/A | 1,192 | N/A |
3/31/2015 | 8,919 | 1,126 | N/A | N/A | N/A |
12/31/2014 | 8,762 | 1,015 | N/A | 1,445 | N/A |
9/30/2014 | 8,423 | 896 | N/A | N/A | N/A |
6/30/2014 | 8,197 | 849 | N/A | 1,059 | N/A |
3/31/2014 | 8,001 | 814 | N/A | N/A | N/A |
12/31/2013 | 7,768 | 760 | N/A | 636 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 1093 의 연간 예상 수익 증가율( 2.7% )이 saving rate( 2.3% 보다 높습니다. ).
수익 vs 시장: 1093 의 연간 수익( 2.7% ) Hong Kong 시장( 11.4% 보다 느리게 성장할 것으로 예상됩니다. 11.4% 연간).
고성장 수익: 1093 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: 1093 의 수익(연간 3.8% ) Hong Kong 시장( 7.8% 보다 느리게 성장할 것으로 예상됩니다. 7.8% 연간).
고성장 수익: 1093 의 수익(연간 3.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 1093 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 10.3 %).